Log in

InVitae Stock Price, News & Analysis (NYSE:NVTA)

$17.99
-0.56 (-3.02 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$17.92
Now: $17.99
$19.33
50-Day Range
$18.02
MA: $21.30
$25.86
52-Week Range
$9.04
Now: $17.99
$28.75
Volume3.47 million shs
Average Volume1.63 million shs
Market Capitalization$1.71 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. Its tests include genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; and screening and testing services in reproductive health, including preimplantation and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone415-374-7782

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$147.70 million
Book Value$2.17 per share

Profitability

Net Income$-129,350,000.00

Miscellaneous

Employees788
Market Cap$1.71 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTA and its competitors with MarketBeat's FREE daily newsletter.


InVitae (NYSE:NVTA) Frequently Asked Questions

What is InVitae's stock symbol?

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

How were InVitae's earnings last quarter?

InVitae Corp (NYSE:NVTA) announced its earnings results on Tuesday, August, 6th. The medical research company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.06. The medical research company had revenue of $53.48 million for the quarter, compared to analyst estimates of $50.17 million. InVitae had a negative return on equity of 58.48% and a negative net margin of 83.69%. The business's quarterly revenue was up 43.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) earnings per share. View InVitae's Earnings History.

When is InVitae's next earnings date?

InVitae is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for InVitae.

What price target have analysts set for NVTA?

7 analysts have issued 1-year target prices for InVitae's shares. Their predictions range from $20.00 to $34.00. On average, they anticipate InVitae's share price to reach $29.00 in the next year. This suggests a possible upside of 61.2% from the stock's current price. View Analyst Price Targets for InVitae.

What is the consensus analysts' recommendation for InVitae?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for InVitae.

What are Wall Street analysts saying about InVitae stock?

Here are some recent quotes from research analysts about InVitae stock:
  • 1. According to Zacks Investment Research, "Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California. " (10/9/2019)
  • 2. Chardan Capital analysts commented, "We liked the new strategic partnerships with biopharma companies, growth in billable tests, and improvement in average cost per sample during the quarter. We see NVTA as a leader among high-growth digital health companies and we see the stock as mispriced compared with its valuation peers. We see the potential for over 50% upside in the name in the next 12 months as Management executes and the stock trades more in line with its valuation comparable." (6/11/2019)

Has InVitae been receiving favorable news coverage?

News stories about NVTA stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. InVitae earned a daily sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for InVitae.

Are investors shorting InVitae?

InVitae saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 15,620,000 shares, an increase of 6.3% from the August 30th total of 14,700,000 shares. Based on an average daily trading volume, of 2,250,000 shares, the short-interest ratio is presently 6.9 days. Currently, 17.3% of the shares of the stock are short sold. View InVitae's Current Options Chain.

Who are some of InVitae's key competitors?

What other stocks do shareholders of InVitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Arista Networks (ANET), Twilio (TWLO), Alibaba Group (BABA), Shopify (SHOP), Roku (ROKU), Gilead Sciences (GILD), Okta (OKTA), Illumina (ILMN) and Veeva Systems (VEEV).

Who are InVitae's key executives?

InVitae's management team includes the folowing people:
  • Dr. Randal W. Scott, Exec. Chairman (Age 61)
  • Dr. Sean E. George, Co-Founder, Pres, CEO & Director (Age 45)
  • Ms. Shelly D. Guyer, Chief Financial Officer (Age 59)
  • Mr. Lee Bendekgey, Sec. & COO (Age 61)
  • Ms. Laura D'Angelo, Head of Investor Relations

When did InVitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

How do I buy shares of InVitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is InVitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $17.99.

How big of a company is InVitae?

InVitae has a market capitalization of $1.71 billion and generates $147.70 million in revenue each year. The medical research company earns $-129,350,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. InVitae employs 788 workers across the globe.View Additional Information About InVitae.

What is InVitae's official website?

The official website for InVitae is http://www.invitae.com/.

How can I contact InVitae?

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]


MarketBeat Community Rating for InVitae (NYSE NVTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  372 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  760
MarketBeat's community ratings are surveys of what our community members think about InVitae and other stocks. Vote "Outperform" if you believe NVTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Dead Cat Bounce

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel